Golden
Cortexyme

Cortexyme

Cortexyme is a company developing novel treatments for Alzheimer's disease and other neurodegenerative disorders.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

June 2018

Cortexyme raises a $76,000,000 series B round from RSL Investments, Pfizer, Takeda Ventures, Lamond Family, Dolby Family Ventures, Verily Life Sciences, Breakout Ventures, Vulcan Capital, EPIQ Capital Group and Sequoia Capital.

People

Name
Role
LinkedIn

Casey Lynch

Chief Executive Officer, Co-Founder



Chris Lowe

Chief Financial Officer



David Hennings

Head of CMC



Kristen Gafric

Vice President of Operations, Co-Founder



Leslie Holsinger

Executive Vice President of Preclinical Development



Robert Galemmo

Vice President of Drug Discovery



Samer Kaba

Chief Marketing Officer



Steve Dominy

Chief Scientific Officer, Co-Founder



Further reading

Title
Author
Link
Type
Date

Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress

Business Wire

News article



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services